<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03534713</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/17/0213</org_study_id>
    <nct_id>NCT03534713</nct_id>
  </id_info>
  <brief_title>Induction Chemotherapy Followed by Standard Therapy in Cervical Cancer With Aortic Lymph Node Spread</brief_title>
  <acronym>ONCOCOL01</acronym>
  <official_title>Phase III Study Comparing Neoadjuvant Chemotherapy With Carboplatin and Paclitaxel Followed by Standard Therapy, With Standard Therapy Alone in Women With Cervical Cancer and Para Aortic Positive Lymph Node.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to determine whether neoadjuvant chemotherapy with&#xD;
      Carboplatin and paclitaxel plus standard cisplatin-based chemoradiation with extended fields&#xD;
      improves overall survival rates compared to standard therapy alone in women with cervical&#xD;
      cancer with paraaortic lymph node involvement.&#xD;
&#xD;
      Women in the experimental arm will receive neoadjuvant chemotherapy with carboplatin and&#xD;
      paclitaxel every 21 days during 3 cycles followed by standard therapy with extended field&#xD;
      external radiation therapy and concomitant chemotherapy. Women in the control arm will&#xD;
      receive standard therapy with extended field external radiation therapy and concomitant&#xD;
      chemotherapy.&#xD;
&#xD;
      310 patients will be recruited during 3 years, with 3 years of follow up period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The survival outcome of patients with carcinoma of the cervix and positive paraaortic lymph&#xD;
      node is poor and the potential benefit of neoadjuvant chemotherapy before extended field&#xD;
      chemoradiotherapy has never been assessed.&#xD;
&#xD;
      Paraaortic nodal spread in cervical cancer is a blind spot in the management of cervical&#xD;
      cancer. It is necessary to evaluate additional treatment.&#xD;
&#xD;
      While the presence of paraaortic nodal metastases often indicates occult systemic disease,&#xD;
      the investigators continue to treat them as a loco-regional disease.&#xD;
&#xD;
      Using neoadjuvant chemotherapy, improvement of overall survival rates is expected in women&#xD;
      with cervical cancer and para-aortic positive lymphadenopathy without increasing the&#xD;
      incidence of further toxicity.&#xD;
&#xD;
      The propose is to determine whether neoadjuvant chemotherapy with Carboplatin and paclitaxel&#xD;
      plus standard cisplatin-based chemoradiation with extended fields improves overall survival&#xD;
      rates compared to standard therapy alone in women with cervical cancer with paraaortic lymph&#xD;
      node involvement.&#xD;
&#xD;
      Secondary objectives will be to compare progression free survival, acute and long term&#xD;
      toxicities, patterns of disease recurrence and patient quality of life between arms This is a&#xD;
      phase III, multicenter, randomized, open label study, recruiting 310 patients during 3 years,&#xD;
      with 3 years of follow up period.&#xD;
&#xD;
      Two groups will be compared : neoadjuvant chemotherapy with Carboplatin and paclitaxel plus&#xD;
      standard cisplatin-based chemoradiation with extended fields, versus standard therapy alone.&#xD;
&#xD;
      Randomization will be stratified according to International federation of gynecology and&#xD;
      obstetrics stages at diagnosis (IB1, IB2, IIA versus IIB-IVA), the size of positive para&#xD;
      aortic lymphadenopathy and the number of node involved and will be balanced by blocks.&#xD;
&#xD;
      Women in the experimental arm will receive neoadjuvant chemotherapy with carboplatin and&#xD;
      paclitaxel followed by standard therapy with extended field external radiation therapy and&#xD;
      concomitant chemotherapy then intracavitary brachytherapy, alone or prior to surgery,&#xD;
      depending on response to treatment according to the current guidelines.&#xD;
&#xD;
      Women in the control arm will receive standard therapy with extended field external radiation&#xD;
      therapy and concomitant chemotherapy then brachytherapy, alone or prior to surgery, depending&#xD;
      on response to treatment according to the current guidelines.&#xD;
&#xD;
      Follow up will be the same between arms. But in experimental arm, during treatment phase, a&#xD;
      clinical examination and biological assessment will be performed before each cycle of&#xD;
      neoadjuvant chemotherapy. Therefore, at the end of neoadjuvant treatment, just before&#xD;
      standard treatment magnetic resonance imaging and positron emission tomography-computed&#xD;
      tomography will be performed.&#xD;
&#xD;
      Then, all Participants will be followed every 4 months until 2 years after randomization and&#xD;
      every 6 months during the third year according to current follow-up guideline for cervical&#xD;
      cancer. Disease response and disease progression will be assessed using clinical examination.&#xD;
      Quality of life will be estimated at baseline, at the end of neoadjuvant chemotherapy, before&#xD;
      intracavitary brachytherapy and at each follow-up visit until 3 years after randomization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>time between random assignment and death resulting from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>fron date of randomization until the date of first documented progression or date of death from any cause, assessed up to 3 years</time_frame>
    <description>time from randomization to first documentation of disease progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>3 years</time_frame>
    <description>classified using the Common Terminology Criteria for Adverse Events and coded using Medical Dictionary for Regulatory Activities dictionary Pattern of disease recurrence will include locoregional recurrence and distant metastasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life questionnaire C30 and CX24</measure>
    <time_frame>3 years</time_frame>
    <description>assessed using the European Organization for Research and Treatment Quality of Life Questionnaire C30 and CX24, all subscales responses will be converted to 0 to 100 scales according to European Organization for Research and Treatment guidelines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patterns of first relapse</measure>
    <time_frame>3 years</time_frame>
    <description>location of relapse or metastasis by magnetic resonance imaging</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">310</enrollment>
  <condition>Cervical Cancer TNM Staging Regional Lymph Nodes (N)</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant chemotherapy+standard therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>neoadjuvant chemotherapy with carboplatin aera Under curve 5 and paclitaxel 175 mg/m² every 21 days during 3 cycles followed by standard therapy with extended field external radiotherapy and concomitant chemotherapy (Cisplatin 40mg/m2 weekly)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard therapy alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard therapy with extended field external radiotherapy and concomitant chemotherapy (Cisplatin 40mg/m2 weekly)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>carboplatin aera Under curve 5 on day 1, every 21 days during 3 cycles</description>
    <arm_group_label>Neoadjuvant chemotherapy+standard therapy</arm_group_label>
    <other_name>Carbo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>paclitaxel 175 mg/m² on day 1, every 21 days during 3 cycles</description>
    <arm_group_label>Neoadjuvant chemotherapy+standard therapy</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin 40mg/m² given once a week during 5 weeks</description>
    <arm_group_label>Neoadjuvant chemotherapy+standard therapy</arm_group_label>
    <arm_group_label>standard therapy alone</arm_group_label>
    <other_name>Platinol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>45 gray to the pelvis and para aortic area over 5 weeks + intracavitary brachytherapy alone or prior to surgery, depending on response to treatment according to the current guidelines</description>
    <arm_group_label>Neoadjuvant chemotherapy+standard therapy</arm_group_label>
    <arm_group_label>standard therapy alone</arm_group_label>
    <other_name>radiation therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women with histologically proven invasive carcinoma of the uterine cervix and para&#xD;
             aortic lymphadenopathy determined by either a positive positron emission tomography&#xD;
             with 2-deoxy-2-[fluorine-18]fluoro- D-glucose integrated with computed tomography or&#xD;
             if negative positron emission tomography computed tomography based on histological&#xD;
             examination of paraaortic lymph node dissection.&#xD;
&#xD;
          -  Performance status Eastern Cooperative Oncology Group 0-2&#xD;
&#xD;
          -  Stage International Federation of Gynecology and Obstetrics IB1 to IVA at diagnosis&#xD;
             with para-aortic lymph node involvement&#xD;
&#xD;
          -  Adenocarcinoma or squamous cell carcinoma or adenosquamous carcinoma&#xD;
&#xD;
          -  Adequate renal function (creatinine &lt;2.0mg/dl)&#xD;
&#xD;
          -  Adequate hepatic function (bilirubin &lt;1.5 times normal and Serum Glutamooxaloacetate&#xD;
             Transferase &lt; 3 times normal)&#xD;
&#xD;
          -  Adequate hematopoietic function Platelet count &gt; 75x10 9/l and Absolute neutrophil&#xD;
             count &gt; 1X10 9/l)&#xD;
&#xD;
          -  Written Informed consent for participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Stage Federation of Gynecology and Obstetrics IVB at diagnosis&#xD;
&#xD;
          -  Others histologies than adenocarcinoma, squamous cell carcinoma and adenosquamous&#xD;
             carcinoma.&#xD;
&#xD;
          -  Women who receive any prior chemotherapy for her cervical cancer&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Prior ( within the last 5 years) malignancies other than non-melanoma skin cancer&#xD;
&#xD;
          -  Inadequate renal, hepatic or hematopoietic function (Cf previously)&#xD;
&#xD;
          -  Cardiovascular pathology New York Heart Association II or more&#xD;
&#xD;
          -  Pre-existing Peripheral neuropathy Common toxicity Criteria grade ≥ 2&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stéphanie MOTTON, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stéphanie MOTTON, MD</last_name>
    <phone>+335 61 32 37 08</phone>
    <phone_ext>33</phone_ext>
    <email>motton.stephanie@iuct-oncopole.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mariavah RODRIGUEZ, CRA</last_name>
    <phone>+335 31 15 64 51</phone>
    <phone_ext>33</phone_ext>
    <email>rodriguez.mariavah@chu-toulouse.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphanie MOTTON, MD</last_name>
      <email>motton.s@chu-toulouse.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Grigsby PW, Heydon K, Mutch DG, Kim RY, Eifel P. Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes. Int J Radiat Oncol Biol Phys. 2001 Nov 15;51(4):982-7.</citation>
    <PMID>11704321</PMID>
  </reference>
  <reference>
    <citation>Varia MA, Bundy BN, Deppe G, Mannel R, Averette HE, Rose PG, Connelly P. Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):1015-23.</citation>
    <PMID>9869224</PMID>
  </reference>
  <reference>
    <citation>Chantalat E, Vidal F, Leguevaque P, Lepage B, Mathevet P, Deslandres M, Motton S. Cervical cancer with paraaortic involvement: do patients truly benefit from tailored chemoradiation therapy? A retrospective study on 8 French centers. Eur J Obstet Gynecol Reprod Biol. 2015 Oct;193:118-22. doi: 10.1016/j.ejogrb.2015.07.017. Epub 2015 Aug 5.</citation>
    <PMID>26295788</PMID>
  </reference>
  <reference>
    <citation>Dueñas-González A, Zarbá JJ, Patel F, Alcedo JC, Beslija S, Casanova L, Pattaranutaporn P, Hameed S, Blair JM, Barraclough H, Orlando M. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol. 2011 May 1;29(13):1678-85. doi: 10.1200/JCO.2009.25.9663. Epub 2011 Mar 28.</citation>
    <PMID>21444871</PMID>
  </reference>
  <reference>
    <citation>Singh RB, Chander S, Mohanti BK, Pathy S, Kumar S, Bhatla N, Thulkar S, Vishnubhatla S, Kumar L. Neoadjuvant chemotherapy with weekly paclitaxel and carboplatin followed by chemoradiation in locally advanced cervical carcinoma: a pilot study. Gynecol Oncol. 2013 Apr;129(1):124-8. doi: 10.1016/j.ygyno.2013.01.011. Epub 2013 Jan 24.</citation>
    <PMID>23353129</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 16, 2018</study_first_submitted>
  <study_first_submitted_qc>May 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2018</study_first_posted>
  <last_update_submitted>July 29, 2020</last_update_submitted>
  <last_update_submitted_qc>July 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoadjuvant chemotherapy</keyword>
  <keyword>Cervical Cancer</keyword>
  <keyword>Paraaortic Lymph Node Involvement</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Paclitaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

